Comprehensive Financial Management LLC Reduces Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Comprehensive Financial Management LLC lessened its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 97.5% in the third quarter, Holdings Channel.com reports. The fund owned 17,656 shares of the company’s stock after selling 688,646 shares during the period. Comprehensive Financial Management LLC’s holdings in Ginkgo Bioworks were worth $144,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Ginkgo Bioworks by 644.5% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company’s stock worth $263,000 after acquiring an additional 27,978 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in Ginkgo Bioworks in the third quarter worth about $4,075,000. PDT Partners LLC bought a new position in shares of Ginkgo Bioworks during the third quarter valued at approximately $1,199,000. Verition Fund Management LLC purchased a new position in shares of Ginkgo Bioworks during the third quarter valued at approximately $792,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Ginkgo Bioworks during the third quarter valued at approximately $1,287,000. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Price Performance

DNA opened at $8.70 on Monday. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.26 and a twelve month high of $75.20. The stock has a market capitalization of $500.07 million, a PE ratio of -0.67 and a beta of 1.09. The firm’s 50 day moving average is $7.93.

Analysts Set New Price Targets

A number of research firms recently weighed in on DNA. TD Cowen raised their price objective on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, September 20th. BTIG Research lifted their price target on Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a research report on Friday, August 23rd. Three analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.58.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.